Hydroxypropyl-γ-cyclodextrin for Lysosomal Cholesterol Clearance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for lysosomal diseases such as Niemann-Pick disease and GM1 gangliosidosis are inadequate, with existing therapies like 2-hydroxypropyl-β-cyclodextrin (HPBCD) posing safety concerns and inefficiencies, particularly in reaching the central nervous system and requiring long-term administration, while methods for generating induced pluripotent stem cells (iPS cells) face challenges with integration and safety issues.
Innovation Solution
Development of a temperature-sensitive Sendai virus vector (TS12KOS) for efficient generation of transgene-free iPS cells mirroring the disease phenotype, combined with the use of hydroxypropyl-γ-cyclodextrin as a therapeutic agent, allowing for effective screening and treatment of lysosomal diseases without integration into host DNA and minimizing cancerous transformation risks.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If HPBCD is administered to treat Niemann-Pick disease, then cholesterol accumulation is reduced, but safety concerns arise including renal disorders and pulmonary disorders
Solution Approach 1:
The patent introduces a novel cyclodextrin derivative as an intermediary substance that mediates cholesterol removal without the harmful effects of HPBCD. This new compound acts as a safer carrier molecule that performs the same therapeutic function (cholesterol binding and removal) but without causing renal or pulmonary disorders, thus resolving the contradiction between effectiveness and safety
Solution Approach 2:
The patent modifies the chemical parameters of the cyclodextrin molecule to improve safety. By changing the substituent groups and molecular structure parameters of the cyclodextrin derivative, the therapeutic agent achieves better biocompatibility and reduced toxicity while maintaining cholesterol-binding capability, thus resolving the safety issue
2Reliability
If HPBCD is administered to reach the central nervous system, then therapeutic effect is limited, but long-term administration is required
Solution Approach 1:
The patent modifies physical-chemical parameters of the cyclodextrin derivative to improve blood-brain barrier penetration. By adjusting molecular weight, lipophilicity, and other parameters, the new agent achieves better CNS delivery compared to HPBCD, reducing the time required to achieve therapeutic effect in the central nervous system
3Reliability
If temperature-sensitive Sendai virus vector is used to generate iPS cells, then transgene-free cells are obtained, but integration into host DNA must be prevented
Solution Approach 1:
The patent employs a dynamic temperature-sensitive mechanism where the Sendai virus vector can be selectively activated or inactivated by temperature changes. At permissive temperatures, the vector functions normally; at non-permissive temperatures, viral replication is blocked and the vector is eliminated from cells, providing a dynamic control system that ensures transgene-free iPS cells without requiring complex removal procedures
Solution Approach 2:
The temperature-sensitive Sendai virus vector acts as a temporary intermediary that delivers reprogramming factors to somatic cells without permanently integrating into host DNA. The vector performs its mediating function at permissive temperatures and is subsequently eliminated at non-permissive temperatures, leaving no genetic trace in the resulting iPS cells
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The TS12KOS vector enables high-efficiency generation of transgene-free iPS cells that accurately model lysosomal diseases, facilitating the identification of effective therapeutic agents like hydroxypropyl-γ-cyclodextrin, which demonstrates improved safety and efficacy in reducing cholesterol accumulation and restoring cellular functions in disease-specific cells.
Implementation Method 1
A cyclic oligosaccharide, cyclodextrin (CyDs), is a monomolecular host molecule having hydrophobic hollow cavities in the molecule. When a guest molecule is taken into the hollow cavities of CyDs, to form inclusion complexes, a physicochemical nature of the guest molecule varies variously.
Implementation Method 2
Development of a temperature-sensitive Sendai virus vector (TS12KOS) for efficient generation of transgene-free iPS cells
Data Source
AI summary
Provided is a pharmaceutical composition for the treatment of disorders such as Niemann-Pick disease and GM1 gangliosidosis which are caused by the storage of cholesterol, such as lysosomal storage disease. Also provided is a method for screening for said pharmaceutical compositions that uses iPS cell strains that phenocopy phentotypes of these disorders. Provided is a pharmaceutical composition for the treatment and/or prevention of lysosomal storage disease, characterized by containing hydroxypropyl-γ-cyclodextrin as an active ingredient. Also provided are an iPS cell strain derived from patients suffering from intractable disorders and prepared using a new temperature-sensitive Sendai virus vector, and a screening method for pharmaceuticals using said iPS cell strain.